Skip to content
sugarisadrug.com
  • Home
  • Diabetes
  • Health News
  • General Sugar
  • Food Choices
  • Insulin
  • Mental Health
  • Stop Eating Sugar
  • Stop Killing Yourself
  • Fructose
  • Sugar Science

Author: sugaradmin

3067-LB: ASC39: An Eloralintide-Like Selective and Potent Oral Small Molecule Amylin Receptor Agonist for the Treatment of Obesity

June 6, 2026 by sugaradmin

Introduction and Objective: Amylin is an attractive target for obesity therapy. Eloralintide is a selective and potent once-weekly subcutaneously administered amylin analog peptide, which has demonstrated promising efficacy and safety profile in a 48-week clinical trial for obesity. ASC39 is a novel oral small molecule amylin receptor agonist development candidate. This study evaluates in vitro […]

Read More
DiabetesLeave a Comment on 3067-LB: ASC39: An Eloralintide-Like Selective and Potent Oral Small Molecule Amylin Receptor Agonist for the Treatment of Obesity

3066-LB: Activating the Adipose Thermogenic Switch: A First-in-Class Ucp1 saRNA Drives Durable, High-Quality Weight Loss in Diet-Induced Obese Mice

June 6, 2026 by sugaradmin

Introduction and Objective: Uncoupling protein 1 (Ucp1) activation drives potent adipose thermogenesis, yet the target is widely considered undruggable by conventional therapeutic modalities. Targeting the Ucp1 promoter with small activating RNA (saRNA) offers a novel RNA activation (RNAa) approach to overcome this barrier. We evaluated the efficacy, body composition, and durability effects of LiCO-saUcp1—an adipose-biased, […]

Read More
DiabetesLeave a Comment on 3066-LB: Activating the Adipose Thermogenic Switch: A First-in-Class Ucp1 saRNA Drives Durable, High-Quality Weight Loss in Diet-Induced Obese Mice

2810-LB: Lifestyle Behavior Screener: Development and Piloting Clinical Implementation

June 6, 2026 by sugaradmin

Introduction and Objective: Lifestyle behaviors (LB) have gained widespread acceptance as a key component of diabetes management since first featured in the 2017 ADA Standard of Care, with emphasis on modifiable LB and practical screening tools to optimize diabetes prevention and management. However, clinical application of existing screening measures remains limited by their length and […]

Read More
DiabetesLeave a Comment on 2810-LB: Lifestyle Behavior Screener: Development and Piloting Clinical Implementation

2227-P: Ask the Experts Mini Fellowship: Preventing the Crisis

June 6, 2026 by sugaradmin

Introduction and Objective: Ask the Experts (EXPERTS) supports U.S. individuals who screen positive for type 1 diabetes islet autoantibodies (IA) and their health care providers (HCPs). Because clinical capacity to monitor and counsel patients with early-stage type 1 diabetes remains limited, we piloted a 1-day CME-accredited mini-fellowship to build HCP confidence and capacity for early-stage […]

Read More
DiabetesLeave a Comment on 2227-P: Ask the Experts Mini Fellowship: Preventing the Crisis

2265-P: Multimorbidity Phenotypes in Diabetes and Their Association with 10-Year Dementia Risk: A Latent Class Analysis in the UK Biobank

June 6, 2026 by sugaradmin

Introduction and Objective: Multimorbidity is common in diabetes and may impact cognitive risk. We used latent class analysis to identify multimorbidity phenotypes and their association with incident dementia.Methods: We included 28,043 adults with diabetes. Twenty-two comorbidity indicators were used to identify multimorbidity classes. We fitted Cox models adjusted for sociodemographic and clinical variables.Results: The incidence […]

Read More
DiabetesLeave a Comment on 2265-P: Multimorbidity Phenotypes in Diabetes and Their Association with 10-Year Dementia Risk: A Latent Class Analysis in the UK Biobank

2643-P: Preliminary Data on Continuing Weight Loss at 52 Weeks and Durable Weight Loss Off Therapy with Nimacimab, a CB1R Antibody, in Combination with Semaglutide

June 6, 2026 by sugaradmin

Introduction and Objective: The CBeyond trial is an ongoing Phase 2a study evaluating nimacimab, a peripherally restricted anti-CB1R inverse agonist mAb, on weight loss. Nimacimab monotherapy, (sc 200 mg QW), is compared to placebo and nimacimab plus semaglutide to semaglutide alone over 26 weeks of treatment, followed by 12 weeks of follow-up off therapy or […]

Read More
DiabetesLeave a Comment on 2643-P: Preliminary Data on Continuing Weight Loss at 52 Weeks and Durable Weight Loss Off Therapy with Nimacimab, a CB1R Antibody, in Combination with Semaglutide

14-PUB: Nutritional and Lifestyle Interventions in the Management of Diabetes in the United States: A Scoping Review

June 6, 2026 by sugaradmin

Introduction and Objective: Nutrition and lifestyle interventions are central to diabetes management, and studies have demonstrated their effectiveness in improving diabetes outcomes. This review aimed at identifying intervention components, delivery settings, and durations that are likely to produce improved clinical outcomes for diabetes individualsMethods: A comprehensive literature search was conducted across 5 electronic databases (MEDLINE, […]

Read More
DiabetesLeave a Comment on 14-PUB: Nutritional and Lifestyle Interventions in the Management of Diabetes in the United States: A Scoping Review

1905-P: Continuous Glucose Monitoring in Patients Aged ≥70 Years Ensures Safe and Effective Intensive Insulin Therapy

June 6, 2026 by sugaradmin

Introduction and Objective: Elderly individuals with diabetes are less likely to be offered continuous glucose monitoring (CGM), as they are often perceived as having difficulties using this technology. We conducted a retrospective observational study to assess the use of CGM in patients with diabetes aged ≥70 years.Methods: Patients aged ≥70 years with diabetes treated with […]

Read More
DiabetesLeave a Comment on 1905-P: Continuous Glucose Monitoring in Patients Aged ≥70 Years Ensures Safe and Effective Intensive Insulin Therapy

2287-P: Trends and Disparities in Mortality Due to Coexisting Diabetes Mellitus and Chronic Obstructive Pulmonary Disease among Adults in the U.S. (1999–2023): Insights from the CDC Wonder Database

June 6, 2026 by sugaradmin

Introduction and Objective: The coexistence of diabetes and chronic obstructive pulmonary disease (DM and COPD) portends poorer outcomes. Yet, nationwide mortality trends and geographic disparities for this comorbidity are poorly characterized.Methods: We analyzed CDC WONDER Multiple Cause-of-Death data (1999-2023) for adults ≥35 with both DM and COPD. Age-adjusted mortality rates (AAMRs per 100,000) were calculated. […]

Read More
DiabetesLeave a Comment on 2287-P: Trends and Disparities in Mortality Due to Coexisting Diabetes Mellitus and Chronic Obstructive Pulmonary Disease among Adults in the U.S. (1999–2023): Insights from the CDC Wonder Database

2694-LB: Primary and Endocrinology Care for Adults with Diabetes following Hyperglycemic and Hypoglycemic Crises in Rural and Urban Areas

June 6, 2026 by sugaradmin

Introduction and Objective: To explore rural-urban differences in follow-up in primary and endocrinology care among adults with diabetes who experienced hyperglycemic or hypoglycemic crises requiring emergency department (ED) or hospital care.Methods: This is a retrospective cohort study leveraging electronic health record data from a large integrated healthcare delivery system in the U.S. Upper Midwest between […]

Read More
DiabetesLeave a Comment on 2694-LB: Primary and Endocrinology Care for Adults with Diabetes following Hyperglycemic and Hypoglycemic Crises in Rural and Urban Areas

Posts navigation

Older posts
Newer posts

Recent Posts

  • Health Benefits of Reading: Why Bedtime Stories Matter
  • Obesity in Your 20s and 30s Linked to Higher Cancer Risk
  • Star Trek Actor Patrick Stewart Dies at 86
  • Fish Oil Supplements May Not Lower Alzheimer’s Risk, Study Finds
  • CGMs & Non-Insulin-Treated T2D, Islet Autoantibody Screening & T1D, Semaglutide CVD Risk Reduction, and more!

Recent Comments

  • A WordPress Commenter on SUCROSE: “PURE” ENERGY AT A PRICE

Archives

  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • November 2024
  • October 2024
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • May 2017

Categories

  • Celebrity Health
  • Diabetes
  • Food Choices
  • Fructose
  • General Sugar
  • Glucose
  • Health News
  • Insulin
  • Mental Health
  • Natural Unrefined Sugar
  • Stop Eating Sugar
  • Stop Killing Yourself
  • Sucrose
  • Sugar Science

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
  • Home
  • Diabetes
  • Health News
  • General Sugar
  • Food Choices
  • Insulin
  • Mental Health
  • Stop Eating Sugar
  • Stop Killing Yourself
  • Fructose
  • Sugar Science

© 2026 Sugar is a DRUG | Sugar Addiction Awareness